Patients with established atherosclerotic cardiovascular (CV) disease remain at increased risk of major adverse cardiovascular events even during optimal lipidlowering therapy. Recent studies using the methods of Mendelian randomization, as well as analyses of data from large statin trials, have concluded that elevated triglyceride (TG) levels contribute to that increased risk. Omega-3 polyunsaturated fatty To appreciate the clinical implications of this result, it is important to understand how the REDUCE-IT trial differed from previous trials, especially with regard to patient enrollment criteria and treatment dosing. We discuss these design features relative to other trials. TG lowering can account for only part of the risk reduction seen with icosapent ethyl; we also consider other potential contributory mechanisms. The trial demonstrated that treatment with a high dose (4 g per day)
amounts, and they have favorable effects on several other markers of CV risk. However, trials of omega-3 PUFAs have had inconsistent findings regarding CV risk reduction. Recently, the REDUCE-IT (Reduction of Cardiovascular Events with EPAIntervention Trial) trial reported that treatment of such high-risk patients with icosapent ethyl, a purified and stabilized ethyl ester of EPA, reduced the risk of the trial's primary CV endpoint by 25% (95% confidence intervals [CI] , 32%-17%; P < .001).
To appreciate the clinical implications of this result, it is important to understand how the REDUCE-IT trial differed from previous trials, especially with regard to patient enrollment criteria and treatment dosing. We discuss these design features relative to other trials. TG lowering can account for only part of the risk reduction seen with icosapent ethyl; we also consider other potential contributory mechanisms. The trial demonstrated that treatment with a high dose (4 g per day)
of the omega-3 polyunsaturated fatty acid (PUFA) icosapent ethyl significantly reduced the risk of ischemic cardiovascular (CV) events and CV death in patients who (a) were on a stable dose of statin, (b) had established CV disease or type 2 diabetes mellitus and at least one additional CV risk factor, and (c) had elevated triglyceride (TG) levels at baseline (>135 or 150 mg/dL). These results were remarkable because they followed a series of major TG-lowering trials that had failed to achieve reductions in CV outcomes in similar groups of patients. [2] [3] [4] [5] [6] Why was REDUCE-IT different? Are the results due solely to lowering of TG levels? What do the results mean for prevention of CV events in patients with established CV disease and elevated TG levels?
| RESIDUAL RISK
In recent decades, statins have become the mainstay of lipid-lowering therapy to reduce risk of CV events in patients with atherosclerotic cardiovascular disease (ASCVD). 5 Statin therapy, which primarily targets low-density lipoprotein cholesterol (LDL-C), has a firmly established role in reducing the risk of CV events by 25% to 35% in such patients. 5 The reduction in risk is related to the absolute reduction in LDL-C levels. 7 However, despite successful lowering of LDL-C levels with statins, patients with ASCVD remain at elevated risk of CV events. 8 PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors further reduce LDL-C levels and CV event rates, but excess CV risk persists (eg, 3-year event rates of approximately 10-13 percent) even in patients with median LDL-C levels of 30 to 40 mg/dL achieved with the combination of a statin and a PCSK9 inhibitor.
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Although non-lipid-related factors-such as smoking, obesity, and diabetes mellitus-account for some of this residual risk, 8 elevated TG levels or low high-density lipoprotein cholesterol (HDL-C) levels have been suspected, since they have been shown to be markers of residual risk in analyses of data from several large statin trials. [11] [12] [13] [14] [15] Other lipid and lipoprotein fractions-such as non-HDL-C, apolipoprotein B, and LDL particle number-are also markers of residual risk. 16 There is a strong inverse relationship between TG levels and HDL-C levels; individuals with low HDL-C levels generally have elevated TG levels and vice versa. 17 However, because observational studies have consistently found a link between low HDL-C and CV risk, [18] [19] [20] [21] [22] [23] several clinical trials were conducted in an effort to reduce CV risk by administering treatments intended to increase HDL-C levels. [24] [25] [26] [27] [28] Although the treatments substantially increased HDL-C levels, only one trial reported a small decrease in major CV event rates, and that decrease was consistent with the degree of LDL-C lowering. 28 We now have a better understanding of why efforts to increase HDL-C levels have had such limited success in reducing CV event rates; recent studies using the method of Mendelian randomization (MR) have supported the conclusion that low HDL-C is not causally associated with increased CV risk. [29] [30] [31] These studies have revealed that genetic variants influencing HDL-C levels do not significantly affect CV risk. Thus, although a low HDL-C level is a marker of increased CV risk, there is now a strong body of evidence from both clinical trials and MR studies that a low HDL-C level is not causally related to an increased risk of CV events. 32 During the era just described, TG re-emerged as an independent CV risk factor. As recently as 2011, a scientific statement from the American Heart Association concluded that the role of TG as an independent causal factor for CV disease was "debatable. 
| EPA and DHA: TG lowering and beyond
Essential fatty acids are those fats that cannot be synthesized by humans; they must be consumed. The two essential fatty acids in the human diet are linoleic acid (LA; an omega-6 FA) and alpha-linolenic acid (ALA; an omega-3 PUFA). 41 LA is the precursor for arachidonic acid, and ALA is the precursor for EPA (and minimally DHA). 42 The main dietary sources of ALA are plants and plant products (such as vegetable oils). In theory, humans possess enzymes necessary to synthesize EPA and DHA from plant-based ALA. In reality, the production of EPA and DHA from ALA is inconsequential. Making matters worse, omega-6 PUFAs, which are often overly abundant in the western diet, dampen the conversion of ALA to EPA and DHA. 42, 43 Thus, many experts consider EPA and DHA to be essential fatty acids. 43 Key dietary sources of EPA and DHA are oily fishes, 42 and several epidemiologic studies have found that groups of people who consume large amounts of such fish have lower rates of CV events and CV death compared with other populations (reviewed in Nishizaki et al. 44 ). Other studies, however, did not find a significant protective effect from consumption of a diet high in fish or EPA or DHA. 45 These studies varied widely with regard to the amount and types of PUFAs consumed by the study population. In 2006, a pooled analysis of prospective studies and randomized trials concluded that consumption of fish or fish oil was associated with a 36% reduction in the relative risk of death from coronary heart disease. 46 Thus, at that time, the prevailing medical opinion was that omega-3 PUFAs from fish had a favorable effect on CV outcomes.
Further support for a role of EPA and DHA in CV risk reduction came from biomarker studies. A pooled analysis of cohort studies conducted around the world found that higher levels of plasma or phospholipid omega-3 PUFAs (EPA, DHA, docosapentaenoic acid
[DPA], and plant-derived ALA) were associated with a modest (approximately 10%) but significantly lower risk of fatal CHD. 47 When evaluating both observational and interventional studies of omega-3
PUFAs, it is important, however, to consider whether the investigators have distinguished ALA, EPA, and, DHA. We now understand that there are substantial differences in their biological activities. 48 Thus, studies that combine the omega-3 PUFAs may fail to discern important health effects that are mostly due to one particular omega-3 PUFA.
Studies have consistently found that fish-oil consumption, as well as consumption of purified EPA or DHA, robustly reduce serum TG levels. [49] [50] [51] [52] [53] ALA, in contrast, has only small and inconsistent effects on TG levels. 49, 50 In most of the studies that found TG-lowering effects of fish oil (or EPA/DHA), participants received 1 g to >4 g of the respective fatty acid per day. 52 The TG lowering effect is linearly dose-dependent, and individuals with higher baseline TG levels exhibit greater declines in absolute TG levels in response to omega-3 PUFA consumption. 40 Reported biological actions of EPA and DHA extend well beyond TG lowering and include effects expected to be cardioprotective. 48, [54] [55] [56] [57] As summarized by Mozaffarian and Rimm, 46 and shown in Figure 1 , fish oil omega-3 PUFAs have been linked with reduced blood pressure and heart rate, as well as decreased platelet aggregation.
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They have also been linked with antiinflammatory actions and stabilization of coronary plaque. [62] [63] [64] [65] Antidysrhythmic actions have been observed in animal or cell models, but their significance in humans is controversial. 40 As shown in Figure 1 , some of the observed cardioprotective effects of omega-3 PUFAs require comparatively high doses of EPA/DHA; for example, lowering of diastolic blood pressure seems to require doses of ≥2 g per day, 59 and antithrombotic effects appear to require even higher doses. 66 It is plausible that other biological effects of omega-3 PUFAs-such as contributions to the mediation of inflammation 67, 68 -may contribute to improvements in CV endpoints, although those relationships need extensive additional testing. 
| RANDOMIZED CONTROLLED TRIALS AND META-ANALYSES

| Fish oil omega-3 PUFAs: Background of clinical studies
A 2011 review analyzed randomized controlled trials, prospective cohort studies, and meta-analyses conducted up to that time and concluded that consumption of fish or fish oil reduced coronary heart disease mortality in populations with and without established CV disease. 40 Three meta-analyses of randomized controlled trials of omega-3 PUFA supplements supported this conclusion. 46 It is important to note that all study participants had elevated TG levels at baseline (most >150 mg/dL).
In the ASCEND and VITAL trials, there were no significant differences between active treatment groups and the placebo groups with regard to rates of non-fatal serious adverse events, including bleeding. 4, 78 In REDUCE-IT, icosapent ethyl was associated with a small but significant increase in rates of hospitalization for atrial fibrillation or flutter vs placebo (3.1% vs 2.1%; P = .004) and a trend toward increased rates of serious bleeding (2.7% vs 2.1%; P = .06). 1 However, prior reviews of bleeding risk associated with pharmacotherapeutic use of omega-3 PUFAs (at daily doses of 1-6 g) concluded that there was no effect on the risk of clinically significant bleeding.
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| WAS REDUCE-IT DIFFERENT?
At first glance, it may seem that the results of REDUCE-IT are at odds with those from prior trials of omega-3 PUFAs. On closer inspection, it becomes evident that the results of REDUCE-IT are consistent with observations from several previous studies. As already discussed, the most recent meta-analysis of omega-3 PUFA supplements for reducing the risk of CV events found that high-risk patients, especially those with elevated TG levels, were more likely to obtain benefit from omega-3 PUFA treatment. 77 Similarly 
Another salient distinction between REDUCE-IT and prior trials was the dose of omega-3 PUFA administered during the treatment period (4 g per day vs ≤850 mg per day in other large trials other than JELIS). The efficacy of high-dose omega-3 PUFA in REDUCE-IT is understandable in the context of JELIS and a recent meta-analysis, which found that higher intakes of omega-3 PUFAs were associated with greater risk reductions. 77 Median plasma levels of EPA among participants in the REDUCE-IT trial in the icosapent ethyl arm were 26.1 μg/mL at baseline and 144 μg/mL after 1 year. In JELIS, EPA levels were substantially higher at baseline (93-97 μg/mL) and increased to approximately 165 /mL during icosapent ethyl treatment. 81 Furthermore, in JELIS, the hazard ratio Finally, it must be noted that icosapent ethyl is a pure, esterified form of EPA, and it was used in two of the three successful trials summarized in Table 1 Although more detailed analyses are needed, the currently available analyses support the conclusion that TG lowering is not the sole mechanism responsible for lowering CV risk among the patients who participated in REDUCE-IT. A similar conclusion was found in a post hoc analysis of the JELIS trial. 85 Previous trials of icosapent ethyl in patients with high TG levels (≥200 mg/dL) found that treatment led to improvements in levels of several atherogenic lipid particles and biomarkers, including apolipoprotein B, very low density lipoprotein cholesterol, lipoproteinassociated phospholipase A2, remnant-like particle cholesterol, and apolipoprotein C-III. 53, 86, 87 Furthermore, preclinical studies have described several other beneficial effects of omega-3 PUFAs that could translate into reductions in rates of clinical events-effects such as improving endothelial function and nitric oxide availability, reducing inflammatory cytokines and enzymes, reducing activation of platelets, and contributing to plaque stabilization (summarized in Ganda et al. 5 ).
| CONCLUSION
The REDUCE-IT trial found that icosapent ethyl (4 g per day), a pure and stable form of the omega-3 PUFA EPA, significantly reduced residual risk of cardiovascular events in patients with ASCVD and elevated TG levels (≥150 mg/dL) who were receiving a stable dose of statin at study entry. On superficial examination, the REDUCE-IT trial appears to be an outlier among trials of omega-3 PUFAs for secondary prevention of CV events. On closer inspection, however, its design and outcomes are consistent with lessons learned from previous studies. Baseline TG levels appear to be a marker of increased likelihood of benefiting from icosapent ethyl treatment, and treatment significantly lowers TG levels. However, currently available analyses suggest that reduction in TG levels likely do not fully account for the beneficial effects of treatment. Despite persistent questions regarding its full mechanism of action, icosapent ethyl significantly ameliorates residual CV risk in patients with ASCVD receiving statin therapy and has been associated with minimal adverse effects. It appears, therefore, that with the results of the REDUCE-IT trial, we have rounded the corner;
we now have in our sights the ability to further reduce the risk of CV events in appropriately selected patients with residual CV risk on optimal statin therapy.
